Arena Pharmaceuticals — Investor Presentation (August 2018)
33 slides from Arena Pharmaceuticals's investor presentation, Aug 9, 2018
Slide 1: Corporate Presentation August 2018
Corporate Presentation August 2018 Exhibit 99.1
Slide 2: Forward-looking statements
This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about the Arena investment thesis, catalysts, value, our investigative stage drug candidates, including with respect to their potential (including to become first or best-in-c
Slide 3: Arena Investment Thesis
*Leerink Analysis & Decision Resources 2016 Arena Investment Thesis Two potential best-in-class, internally developed drug candidates to Ph 3 Olorinab data readout in Crohn’s pain in September Ralinepag Ph 3 program initiated in PAH; OLE data in H2 Etrasimod Ph 3 initiation in UC Etrasimod program i
Slide 4: Differentiated Assets with High-Value Potential
Differentiated Assets with High-Value Potential Current Publicly Disclosed Pipeline Program Therapeutic Area/Indication PC Ph 1 Ph 2 Ph 3 Status Etrasimod Optimized Activity S1P Receptor Modulator Ulcerative Colitis (UC) Study 1 Ph 3 Planning Ulcerative Colitis (UC) Study 2 Ph 3 Planning Crohn’s Dis
Slide 5: Etrasimod
Oral, Next Generation, S1P Receptor Modulator with Optimized Activity Being Evaluated for Multiple Immune-Inflammatory Diseases Etrasimod
Slide 6: Etrasimod Phase 2 efficacy and safety summary
Ph 2 Efficacy Dose dependent lymphocyte reduction Strong remission data – 33% of 2 mg patients achieved remission with heavy pretreatment with biologics Strong and consistent mucosal healing Fast onset - important in flare state Novel orals Existing biologics S1Ps JAKs $18-23B IBD Market Globally1 P
Slide 7: S1P Modulation May Avoid Off-Target Activity
S1P Modulation May Avoid Off-Target Activity S1P = Sphingosine 1-phosphate; UC = ulcerative colitis. *Data generated at Arena or under sponsored research by Arena Etrasimod’s Highly Selective Etrasimod Decreased Inflammation & Improvement in Immune-Inflammatory Disorders Positive Outcome Negative Ou
Slide 8: Etrasimod Does Not Induce S1PR2 Internalization
Etrasimod Does Not Induce S1PR2 Internalization (In Vitro Studies) Arena Data presented at ASPET 2017 at Experimental Biology (EB); DMSO = dimethylsulfoxide; S1P = sphingosine-1-phosphate In Contrast with Other S1P Modulators -12 -11 -10 -9 -8 -7 -6 -5 log [Agonist] (M) Mean Fluorescence Intensity (
Slide 9: Receptor Pharmacology and Endothelial Barrier Function
Montrose et al. S1P1 localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity. J Lipid Res. 2013 Mar; 54(3): 843–851; Spiegel S et al. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Immunology Rev (2011); Blackenbach KV et al., Frontiers in Ph
Slide 10: S1P1 Signaling Profile and Barrier Function
Ungaro et al. Lancet 2017; 389:1756-70. Baumgart & Sandborn Lancet 2012; 380:1590-1605. Jain & Bhatti Neurology 2012;78:672-689. Sanna et al Nat Chem Biol 2006;2:434-441. Etrasimod’s S1P1 Signaling Profile May Have Beneficial Effects on Barrier Function Implications for Efficacy Better mucosal heali
Slide 11: Etrasimod Has a Quick Offset of Action
Ozanimod Similar to Gilenya; Etrasimod Only 2nd Generation Sources: 1-Tran JQ et al, J Clin Pharmacol. 2017;57:988-996. 2-Kovarik JM et al, J Clin Pharmacol. 2004;44:535-537. 3- ADP334 P1 Data on File; *Active metabolite Etrasimod Has a Quick Offset of Action Note – Data Collected from Separate Stud
Slide 12: Etrasimod Has a Quick Onset of Action
Phase 1 Data *After dose escalation of ozanimod (0.3 mg/d on days 1–3; 0.6 mg/d on days 4 and 5; 1 mg/d on days 6 and 7; and 3 mg/d on days 8–10. Data truncated at day 11 (ozanimod) and 15 (etrasimod) to show on-treatment onset effects Sources: 1-Tran JQ et al, J Clin Pharmacol. 2017;57:988-996. 2-
Slide 13: Etrasimod Phase 2 Trial in Ulcerative Colitis (OASIS)
Randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study Etrasimod Phase 2 Trial in Ulcerative Colitis (OASIS) 12-Week Induction Phase 12-Week Treatment Period Transition Directly into 36-Week Extension Study (APD334-005) 156 Patients Randomized 1:1:1 Week 14 Follow-up Safety
Slide 14: Phase 2 Primary Endpoint: 3-Domain MCS
Δ = -0.43 (p = 0.146) Placebo Etrasimod 1 mg Etrasimod 2 mg Δ = -0.99 (p = 0.009) Change on 9-Point Scale Including Rectal Bleeding, Stool Frequency, Endoscopy LS=least square; Δ LS mean difference from placebo. LS mean was estimated using an ANCOVA model that includes current oral corticosteroid th
Slide 15: Phase 2 Secondary Endpoint: Endoscopic Improvement
Δ = 4.1% (p = 0.306) Δ = 24.4% (p = 0.003) Proportion of Patients with Mayo Clinic Subscore of 0 or 1 points Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antagonists Phase 2 Secondary Endpoint: Endoscopic
Slide 16: Phase 2 Clinical Remission (3-Domain)
Proportion of Patients with Endoscopy, Rectal Bleeding and Stool Frequency Mayo Clinic Subscore of ≤ 1 point and Stool Frequency Improvement of ≥ 1 point Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antago
Slide 17: Phase 2 Clinical Remission (4-Domain) in UC
Proportion of Patients with TMCS ≤ 2 points and No Subscore > 1 point Etrasimod: Post-hoc analysis. Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antagonists.. Sources: Ozanimod: Sandborn, et al. NEJM 2016;
Slide 18: Clinical Remission (4-Domain) in UC Studies of S1P Modulators
Proportion of Patients with with Total Mayo Clinic Score ≤ 2 points and No Subscore > 1 point Total MCS = Mayo Clinic Score. Etrasimod: Post-hoc analysis. Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antag
Slide 19: Phase 2 Safety Profile
Phase 2 Safety Profile Etrasimod was generally safe and well tolerated Adverse events were predominantly mild to moderate No serious adverse events (SAEs) at the 2 mg dose Impact on HR and AV conduction was low throughout the study with no discontinuations related to bradycardia or AV block. No SAEs
Slide 20: Ralinepag
A Next-Generation, Oral, Selective Prostacyclin Receptor (IP) Agonist for the Treatment of Pulmonary Arterial Hypertension Ralinepag
Slide 21: Potential to Redefine Treatment Paradigm in PAH
Potential to Redefine Treatment Paradigm in PAH 1. Decision Resources 2016 2. Barst RJ N Engl J Med 1996; 334:296-301 *Least squares mean change from baseline; non parametric testing to account for non-normal distribution Phase 3 Ralinepag Oral QD Ralinepag 6.5-10x improved potency compared to selex
Slide 22: Ralinepag's More Potent IP Agonism
Vasodilation1 (Normal Human Tissue) Inhibition of SMC Proliferation2 (Human PAH Tissue) Platelet Inhibition3 (Normal Human Cells) Translates to Improved Tissue Responses vs. Selexipag* in Vitro *MRE-269 is the active metabolite of selexipag. cAMP, cyclic adenosine monophosphate; PAH, pulmonary arter
Slide 23: Ralinepag's unique PK profile
Ralinepag’s unique PK profile is expected to provide a low peak-to-trough ratio, approximating continuous IV infusion Compound t½ (Hr) Ralinepag ~20–26 hrs3 Selexipag 8 hrs2 Treprostinil 4.5 hrs1 Long T½ low peak to trough Short T½ high peak to trough Long T½ modified release 0 24 36 48 60 72 12 Tim
Slide 24: Ralinepag Significantly Improved Pulmonary Vascular Resistance
Ralinepag Significantly Improved Pulmonary Vascular Resistance (PVR); ITT Population Unprecedented Ph 2 Efficacy in Contemporary Patient Population Secondary Endpoint Percent change (SE) from baseline 25 15 5 -5 -15 -25 -35 Ralinepag (n = 40) -29.8% (P = 0.03)* -20.1% Placebo (n = 21) 9.6% Mean abso
Slide 25: PVR Changes With Ralinepag and Historical Flolan
*PVR, change in least squares mean from placebo; **Flolan: Barst et al NEJM 1996 Feb 1;334(5): 296-301 PVR Changes With Ralinepag and Historical Flolan® Note: No direct head-to-head data available - Caution advised when comparing data across clinical studies Ralinepag (n=40) Placebo (n=40) Placebo (
Slide 26: PVR Changes With Ralinepag and Historical Selexipag
ITT Study Populations *PVR, change in geometric mean expressed as a percentage of the baseline value; **Selexipag data from P2 study: Medical Review CDER Application: 207947Orig1s000 PVR Changes With Ralinepag and Historical Selexipag Placebo (n=10) Selexipag (n=33) Placebo (n=21) Ralinepag (n=40) -
Slide 27: Phase 2 Safety and Tolerability
Phase 2 Safety and Tolerability The overall safety and tolerability profile consistent with the known profile of the prostacyclin therapy class Adverse events that occurred most frequently on ralinepag were similar to the on-target effects expected for prostacyclin therapies: Headache, nausea, diarr
Slide 28: Phase 3 Program Comprehensive Approach
Ralinepag vs. Placebo + Current Therapy ~140 patients Evaluate peak oxygen uptake (VO2) via CPET 7-month fixed treatment duration 2:1 randomization Expect to initiate in Q4:18 Ralinepag vs. Placebo + Current Therapy ~700 patients Evaluate time to first clinical worsening event Event-driven duration;
Slide 29: Olorinab
Peripherally Restricted, Highly–Selective, Full Agonist to Cannabinoid 2 Receptor (CB2) Being Evaluated for Treatment of Pain Associated with Crohn’s Disease Olorinab
Slide 30: Unmet Need in Non-Opioid Pain Management
Status Ph 2 ongoing for the treatment of pain associated with Crohn’s disease, data Q3’18 Unmet Need in Pain Opioid epidemic is a public health emergency No drugs developed for the treatment of visceral pain including: Inflammatory bowel disease Interstitial cystitis Pancreatitis Endometriosis Chron
Slide 31: CB2 Receptor Expression in the GI Tract
CB2 receptors represent a pathophysiological mechanism in GI tract to regulate abnormal motility, modulate intestinal inflammation & limit visceral sensitivity/pain CB2 Receptor Expression in the GI Tract CB2 receptors located in target tissue, neurons & local immune cells in GI tract CB2 receptor a
Slide 32: Arena Investment Thesis
*Leerink Analysis & Decision Resources 2016 Arena Investment Thesis Two potential best-in-class, internally developed drug candidates to Ph 3 Olorinab data readout in Crohn’s pain in September Ralinepag Ph 3 program initiated in PAH; OLE data in H2 Etrasimod Ph 3 initiation in UC Etrasimod program i
Slide 33: Thank You
THANK YOU NASDAQ: ARNA
Arena Pharmaceuticals — Investor Presentation (August 2018) on 6ix